On September 4, 2019 Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, reported that it has appointed Randall Schatzman, Ph.D. to the position of chief executive officer and as a member of Bolt’s board of directors (Press release, Bolt Biotherapeutics, SEP 4, 2019, View Source [SID1234539253]). Dr. Schatzman brings over 30 years of biotech leadership experience to Bolt and most recently served as president and CEO of Alder BioPharmaceuticals, Inc. where he successfully led the company from inception through registration-enabling activities including positive Phase 3 trials and significant fund raising.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am very pleased to welcome Randy as our chief executive officer," said Peter Moldt, of Novo Ventures and executive chairman of the board of Bolt Biotherapeutics. "We believe our ISAC technology has great potential and look forward to Randy’s expert leadership to successfully advance Bolt’s programs and therapeutic candidates."

"ISACs represent an important evolution of cancer immunotherapies with the potential to have a profound impact on a significant number of cancer patients, and I’m excited to have the opportunity to play a role in their development," stated Dr. Schatzman. "I am joining an experienced cancer immunotherapy team which includes alumni of the industry’s premier cancer therapeutics companies and Ed Engleman, M.D., Bolt founder, and inventor of the technology underlying the first-ever FDA-approved immunotherapy. The Bolt team is progressing on a strategy to quickly demonstrate the efficacy and safety of our novel technology and expect to enter the clinic in the first half of next year. Bolt’s impressive preclinical data support optimism for our ISACs by demonstrating not only complete eradication of hard to treat tumors but also establishment of immunological memory which enables prevention of tumor re-establishment, promising improved durability of clinical response for patients."

About Randall Schatzman, Ph.D. Dr. Randall Schatzman joins Bolt Biotherapeutics with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

About Bolt Biotherapeutics’ Immune-Stimulating Antibody Conjugate (ISAC) Platform Technology
The Boltbody platform consists of Immune-Stimulating Antibody Conjugates (ISAC) that harness the ability of TLR agonists to convert cold tumors into immunologically hot tumors thereby illuminating tumors to the immune system allowing them to be invaded by tumor killing cells. Boltbody ISACs have demonstrated the ability to eliminate tumors following systemic administration in preclinical models and have also led to the development of immunological memory, which is predicted to translate into more durable clinical responses for patients.